Completed PHASE1 INTERVENTIONAL 1-arm NCT00573495

Multipeptide Vaccine for Advanced Breast Cancer

A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer

Sponsor: University of Pennsylvania

Conditions Breast Cancer Breast Neoplasm Cancer of the Breast Carcinoma, Ductal

Interventions hTERT/Survivin Multi-Peptide Vaccine

Updated 6 times since 2017 Last updated: Sep 27, 2016 Started: Nov 30, 2007 Primary completion: Jul 31, 2011 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer and Breast Neoplasm and is currently completed. University of Pennsylvania leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Pennsylvania

Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States